Taeyoung Choi

Jul 17, 2024 | nejm.org | Ziyad Al-Aly |Taeyoung Choi

Published July 17, 2024 N Engl J Med 2024;391:515-525 DOI: 10.1056/NEJMoa2403211 For permission requests, please contact NEJM Reprints at [email protected] Postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), also called “long Covid,” can affect many organ systems.1,2 The risk of PASC appears to increase with greater severity of infection and with the presence of preexisting medical conditions, and the risk appears to decrease after coronavirus...

May 15, 2024 | jamanetwork.com | Yan Xie |Taeyoung Choi |Ziyad Al-Aly

In the first year of the COVID-19 pandemic, risk of death in people hospitalized for COVID-19 was substantially higher than in people hospitalized for seasonal influenza.1,2 The risk of death due to COVID-19 has since declined.

Jan 31, 2024 | jamanetwork.com | Rita Rubin |Melissa Suran |Yan Xie |Taeyoung Choi

Anyone who watches television has probably seen the Pfizer commercial with the tagline, “If it’s COVID, Paxlovid.” That might be a catchy slogan, but, apparently, a lot of people aren’t getting the message. The US Food and Drug Administration (FDA) approved Paxlovid last May for the treatment of mild to moderate COVID-19 in adults who are at risk of progression to severe disease.

Dec 14, 2023 | thelancet.com | Yan Xie |Taeyoung Choi |Ziyad Al-Aly

Research in contextEvidence before this studyWe searched PubMed for studies published between Dec 12, 2019, and Sept 10, 2023, using the search terms “COVID-19” and “SARS-CoV-2” in combination with the search terms “seasonal influenza”, “flu”, OR “influenza”, with no language restrictions.

Apr 25, 2023 | bmj.com | Yan Xie |Taeyoung Choi |Ziyad Al-Aly

Intended for healthcare professionals Toggle navigation The BMJ logo Toggle top menu ResearchMolnupiravir and risk...